Q-Pin

Q-Pin

quetiapine

Manufacturer:

Amarox
Concise Prescribing Info
Contents
Quetiapine
Indications/Uses
Schizophrenia, manic & depressive episodes associated w/ bipolar disorder.
Dosage/Direction for Use
Adult Schizophrenia Total daily dose for 1st 4 days: 50 mg (day 1), 100 mg (day 2), 200 mg (day 3), 300 mg (day 4) to be taken twice daily. From day 4 onwards, titrate up to 300-450 mg/day. Range: 150-750 mg/day. Manic episodes associated w/ bipolar disorder Administer twice daily as monotherapy or as adjunct to mood stabilizers. Total daily dose for the first 4 days: 100 mg (day 1), 200 mg (day 2), 300 mg (day 3), 400 mg (day 4). Further dosage adjustment up to 800 mg/day by day 6 should be in increments of not >200 mg daily. Dose may be adjusted w/in 200-800 mg/day. Usual effective dose: 400-800 mg/day. Depressive episodes associated w/ bipolar disorder Administer once daily at bedtime. 50 mg (day 1), 100 mg (day 2), 200 mg (day 3), 300 mg (day 4). May be titrated to 400 mg on day 5 & up to 600 mg by day 8. Elderly, hepatic impairment Initially 25 mg/day, increased daily by increments of 25-50 mg to an effective dose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant administration w/ cytochrome P450 3A4 inhibitors eg, HIV-PIs, azole-antifungal agents, erythromycin, clarithromycin & nefazodone.
Special Precautions
Increased risk of suicidal thoughts, self-harm & suicide-related events. Increased incidence of extrapyramidal symptoms. Tardive dyskinesia. Somnolence & related symptoms eg, sedation, orthostatic hypotension & related dizziness. Sleep apnea syndrome. Patients receiving concomitant CNS depressants & who have history or are at risk eg, overwt/obese, male patients. Anti-cholinergic (muscarinic) effects. Patients w/ current diagnosis or prior history of urinary retention, significant prostatic hypertrophy, intestinal obstruction or related conditions, increased IOP or narrow angle glaucoma; history of seizures. CV & cerebrovascular disease or other conditions predisposing to hypotension or family history of QT prolongation. Patients w/ suspected cardiomyopathy or myocarditis. Neuroleptic malignant syndrome. Severe neutropenia w/o infection. Agranulocytosis in patients w/o pre-existing risk factors. Discontinue in patients w/ neutrophil count <1.0 x 109/L. Monitor wt; blood glucose. Increased triglycerides, LDL & total cholesterol & decreased HDL cholesterol. Medicines known to increase QT interval or w/ neuroleptics, especially in elderly, in patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalaemia or hypomagnesaemia. Patients w/ history of alcohol or drug abuse. Patients at risk for aspiration pneumonia. Venous thromboembolism, constipation & intestinal obstruction, pancreatitis. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients should be advised not to drive or operate machinery. Pregnancy. Avoid breast-feeding during treatment. Neonatal w/drawal symptoms.
Adverse Reactions
Decreased haemoglobin; elevated serum triglycerides, elevated total cholesterol (predominantly LDL cholesterol), decreased HDL cholesterol, wt gain; dizziness, somnolence, headache, extrapyramidal symptoms; dry mouth; w/drawal symptoms. Leucopenia, decreased neutrophil count, increased eosinophils; hyperprolactinaemia, total T4, free T4, total T3 decreased, increased TSH; increased appetite, blood glucose increased to hyperglycaemic levels; abnormal dreams & nightmares, suicidal ideation & behaviour; dysarthria; tachycardia, palpitations; blurred vision; orthostatic hypotension; dyspnoea; constipation, dyspepsia, vomiting; elevated ALT, elevated γ-GT levels; mild asthenia, peripheral oedema, irritability, pyrexia.
Drug Interactions
Decreased plasma conc w/ concomitant use of strong hepatic enzyme inducer eg, carbamazepine or phenytoin. In combination w/ other centrally-acting drugs, alcohol, anticholinergic medications, drug causing electrolyte imbalance or increase QT interval. Increased clearance w/ carbamazepine, phenytoin & thioridazine. Grapefruit juice. False positive results in enzyme immunoassays for methadone & TCAs.
MIMS Class
ATC Classification
N05AH04 - quetiapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics.
Presentation/Packing
Form
Q-Pin FC tab 200 mg
Packing/Price
6 × 10's
Form
Q-Pin FC tab 300 mg
Packing/Price
6 × 10's
Form
Q-Pin FC tab 100 mg
Packing/Price
6 × 10's
Form
Q-Pin FC tab 25 mg
Packing/Price
6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in